Roundup: AWAK baggage $20M in Sequence B funding and extra briefs

AWAK baggage $20M in Sequence B funding

Regardless of a difficult market situation, Singapore-based medtech AWAK Applied sciences has raised greater than $20 million in a Sequence B funding spherical – one of many largest funding raises in Southeast Asia this yr. The spherical was co-led by Lion X Ventures and Vickers Enterprise Companions. 

AWAK is growing a conveyable peritoneal dialysis machine that permits customers to bear dialysis anyplace, foregoing lengthy hours of stationary remedy and being related to large-sized machines in hospitals and clinics. 

Primarily based on a press launch, the proceeds from the funding spherical will go to finishing AWAK’s ongoing human scientific trial with Singapore Common Hospital, which is being carried out forward of its last pivotal trial in the USA in 2025. 

The fund may even be used for growing complementary merchandise that promote dwelling dialysis and combine digital options for bettering home-based care of power kidney illness sufferers.

On-line pharmacy MedEasy nets $750k seed funding

MedEasy, a web-based pharmacy in Bangladesh, has scored $750,000 in a seed funding spherical participated by Seedstars Worldwide Ventures, Doha Tech Angels, Startup Bangladesh Restricted, Accelerating Asia, and nVentures, amongst different traders.

The funds will probably be used to refine its operation, improve its platform options, attain extra customers, and advance R&D, a press assertion mentioned.

Because it launched two years in the past, the startup has now over 150,000 customers. Except for rising its buyer base, MedEasy additionally plans to launch a subscription-based characteristic, a digital well being monitoring system, and an appointment-booking market. 

Switzerland OKs DeepBio’s AI prostate most cancers analysis assist software program 

Medical AI startup DeepBio from South Korea has obtained regulatory approval from Switzerland for its AI-powered diagnostic assist software program for prostate most cancers.

The Swiss Company for Therapeutic Merchandise has cleared DeepDx Prostate for commercialisation in Switzerland, in keeping with a press launch.

The AI product, which has additionally been permitted in Europe, analyses complete slide photographs of prostate needle biopsy tissues utilizing AI to detect and localise areas of curiosity and classify them by severity. 

Samsung SDS-spinoff Wellysis’s ECG patch will get US FDA approval

Wellysis, a Samsung SDS spinoff firm primarily based in Seoul, has acquired the approval of the USA Meals and Drug Administration for its wearable ECG patch. 

The S-Patch Ex incorporates a bio-processor for capturing correct ECG waveforms. The light-weight machine might be built-in with cellphones, tablets, and watches, and can be appropriate with any commercially obtainable electrodes and batteries. 

The US FDA approval comes two years after the machine has been granted a CE mark in Europe. S-Patch Ex is presently being offered in 14 nations worldwide, together with the UK, Australia, Thailand and India. 

Binance.US Sees Extra Key Departures

Former Chief Income Officer Pleads Responsible